The headlines are screaming.
New non-invasive tests for endometriosis are rolling out in the UK. Women with years of undiagnosed pelvic pain are hoping this is finally it. The breakthrough.
The truth is more nuanced.
Endometriosis hits 10% of women of reproductive age globally. Yet it remains one of the hardest conditions to diagnose. It is a chronic inflammatory disease where uterine lining tissue grows outside the uterus. On the ovaries. Fallopian tubes. The bowel. The result? Excruciating pain, disrupted relationships, and work burnout.
In the UK, an inquiry found more than half of 10,00+ women saw their GP over ten times before getting a diagnosis. Ten.
Until now, the gold standard was laparoscopy. General anesthesia. A camera through an incision in your abdomen. Invasive. Expensive. Risky. For many, it was the only path to validation. And a massive barrier.
Then came July 7.
The UK’s National Institute for Health and Care Excellence (NICE) authorized two new tests: Endotest and EndoSure. They can now be used in primary care to speed up diagnosis.
But not yet as a final verdict.
How Do These New Non-Invasive Tests Actually Work?
These tools are meant for specific cases. NICE says they are only for women who still suspect endometriosis despite a normal exam and unclear imaging results. They are additions to clinical practice. Not replacements.
Endotest looks at saliva.
It doesn’t measure one inflammatory marker. It hunts for microRNA patterns.
“It analyzes patterns of microRNAs… small regulatory molecules involved in gene expression,” explains Dr. Jila Senemar.
In theory, these patterns create a disease-specific signature. The lab checks for it. If the pattern matches, it suggests endometriosis.
Dr. Senemar points out a critical caveat. It’s not just about seeing different RNA in sick vs. healthy women. Can the test distinguish endometriosis from other conditions that mimic it? That is the missing data.
EndoSure is weirder. And faster.
It uses sensor pads on your abdomen. It measures electrical signals in the gut. You fast for 6-8 hours. You drink water until full during the 45-minute session to boost gut activity signals.
No blood. No saliva.
Results are immediate. Compare that to waiting years for a surgical referral. The speed difference is staggering.
But here is the catch.
Why NICE Is Being So Cautious About Approval
NICE didn’t approve these tests because they are “proven.”
It is a three-year trial.
NICE is allowing use while collecting real-world evidence. The companies run the data generation. NICE reviews progress every year.
Dr. Senemar is wary of overselling.
“A diagnostic test almost always performs better when the disease is already relatively common in the test group,” she says.
Current tests only worked in populations with known chronic pelvic pain and high suspicion. Move them to the general population? The accuracy drops. False positives spike.
That is why the rollout is slow. They need to know if EndoSure and Endotest work in the real world. Not just in clinics where endometriosis is expected.
Where Do Women In The U.S. Stand Right Now?
If you are in America. You cannot walk in and order Endotest.
The US regulatory landscape is different. These tests still face FDA review, insurance hurdles, and adoption gaps.
We might have to wait until the UK gathers its evidence.
Though science is moving there too. A recent study showed a blood test identified endometriosis with 95% accuracy. But it is not yet widely available.
Dr. Senemar’s advice holds weight across oceans. View non-invasive testing as a tool. Not an answer. Diagnosis still relies on the full picture. Symptoms. Exam. Imaging. Sometimes surgery.
The field is moving. That matters for millions who heard their pain was “just cramps.”
But until the evidence is solid, the system is still broken for many.
Document everything. Advocate. Push for referrals. The science is catching up. Slowly.
Are we ready? Maybe. But be careful not to mistake a first step for a finish line.
